IMNN Stock Forecast: Imunon, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Imunon, Inc. is $10. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 12 of 100 as at 21 Nov 2026 — in the weakest quartile.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Imunon, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (82): The share price has been relatively steady.
Issuance (3): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
IMNN stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on IMNN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 17 Apr 2026 | Maxim Group | Initiates | Buy | $10 |
| 19 May 2025 | D. Boral Capital | Downgrade | Hold | — |
| 13 May 2025 | D. Boral Capital | Maintains | Buy | — |
| 7 May 2025 | D. Boral Capital | Maintains | Buy | — |
| 26 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 24 Mar 2025 | D. Boral Capital | Maintains | Buy | — |
| 27 Feb 2025 | D. Boral Capital | Maintains | Buy | — |
| 19 Feb 2025 | D. Boral Capital | Maintains | Buy | — |
| 24 Jan 2025 | D. Boral Capital | Maintains | Buy | — |
| 19 Dec 2024 | D. Boral Capital | Maintains | Buy | — |
| 19 Dec 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 11 Dec 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 10 Dec 2024 | D. Boral Capital | Maintains | Buy | — |
| 25 Nov 2024 | D. Boral Capital | Maintains | Buy | — |
| 11 Nov 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 7 Nov 2024 | EF Hutton | Maintains | Buy | — |
| 31 Oct 2024 | EF Hutton | Maintains | Buy | — |
| 23 Sept 2024 | EF Hutton | Initiates | Buy | — |
| 15 Aug 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 5 Aug 2024 | HC Wainwright & Co. | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for IMNN.
This page is one stock. Monday covers all of them.
IMNN appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
IMNN vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Imunon, Inc. returned −85.5% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
IMNN analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- 0.3×
- EV / EBITDA
- —
Cheaper than 92% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −429.7%
- Return on assets
- −78.0%
- Dividend yield
- —
Higher than 3% of US stocks
Higher than 4% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Imunon, Inc. has a market value of $3.5M and an enterprise value of $6.8M.
Revenue in the twelve months to 31 Mar 2026: $0.0.
Net income over the same four quarters: −$14.6M.
Free cash flow in the twelve months to 31 Mar 2026: −$15.1M, after $21K of capital spending.
Imunon, Inc. employs 20 people.
Data provided by Twelve Data
IMNN and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at IMNN’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Imunon, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about IMNN
What is the IMNN stock price forecast for 2026-2027?
The median 12-month analyst price target for Imunon, Inc. is $10, with estimates ranging from $6 to $25. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is IMNN stock a buy right now?
Of the 4 analysts covering Imunon, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Imunon, Inc. 12 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank IMNN?
As at 21 Nov 2026, Imunon, Inc. ranks 12 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Volatility (82 of 100).
Will IMNN stock go up?
No one can know that. What the data says: the median 12-month target from 4 analysts is $10, and Ticker Nerd's factor model ranks Imunon, Inc. 12 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the IMNN stock forecast for 2030?
No analyst covering Imunon, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IMNN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6 to $25 over the next 12 months.
How has IMNN stock performed over the past year?
Imunon, Inc. returned -85.5% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Imunon, Inc. do?
Imunon Inc. is a clinical-stage biotechnology company focused on developing DNA-based immunotherapies and vaccines for difficult-to-treat diseases. The company’s current portfolio centers on proprietary non-viral DNA platforms designed to activate the body’s immune system at the site of disease, with applications in oncology and infectious diseases.
About Imunon, Inc.
Imunon Inc. is a clinical-stage biotechnology company focused on developing DNA-based immunotherapies and vaccines for difficult-to-treat diseases. The company’s current portfolio centers on proprietary non-viral DNA platforms designed to activate the body’s immune system at the site of disease, with applications in oncology and infectious diseases. Its lead program, IMNN-001, is being developed as a localized immunotherapy for advanced ovarian cancer, while its PlaCCine platform supports nucleic acid vaccine research for infectious disease targets. Imunon also advances additional preclinical and early-stage programs across solid tumors and viral indications. Headquartered in Lawrenceville, New Jersey, Imunon plays a specialized role in the biotechnology market by pursuing platform-based treatments that combine immunology, gene delivery, and cancer therapy research.
CEO Dr. Stacy R. Lindborg Ph.D. · 20 employees · United States · https://imunon.com